2 firms to hold until you retire and beyond

Brexit looks like a sideshow for these enduring businesses.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Just a handful of firms in the FTSE 100 have defensive, growing businesses that tend to show resilience as the effects of macroeconomic cycles put pressure on others. I’m happy to invest in those firms until the day I retire and beyond, with a reasonable expectation that my total return will be positive. 

If you’re looking for buy-and-forget investments that can help you grow your funds while you get on with your life, it’s worth considering these few well-positioned companies. Today, I’m looking at two of them: AstraZeneca (LSE: AZN) and Imperial Brands (LSE: IMB).

Cash, cash, cash

Cash is almost everything when it comes to spotting a great business. To be specific, if a business isn’t generating steady flows of incoming cash it doesn’t qualify as a great business, in my view. Businesses exist to make money and we need to see that in cold, hard cash, not just in an accountant’s figure for profits written on a profit and loss statement.

If a firm’s financial record shows a lumpy pattern of net cash generated from operations, there’s a good chance the business suffers from the effects of trading cycles. That’s not good for a long-term buy-and-hold investment. AstraZeneca and Imperial Brands aren’t like that. They both have a good record of generating reliable net cash from operations tending to come in around the level of profits, so earnings have support from real cash flows. 

Cash pays dividends and regular, growing dividends will make a big contribution to the total returns for investors in the years to come from these two firms. 

Consumer goods

AstraZeneca and Imperial Brands are able to generate steady flows of cash from their businesses regardless of macroeconomic conditions. I think that’s because they both deal in ‘essential’ consumer goods with short life spans. Customers rarely forego AstraZeneca’s medical treatments or Imperial Brand’s tobacco products no matter how hard times become. They keep buying over and over again, and that behaviour makes cash flow and dividend payments predictable and reliable. That’s why investor’s label such firms as ‘defensive’.

Contrast these defensive stalwarts with more cyclical firms such as builders, banks and retailers and it’s easy to appreciate their enduring appeal. Companies with a high level of cyclicality in their operations deal in goods and services that last longer, tend to cost more, and that are easily avoided when consumers hit hard times. Cash generation from the cyclical firms can be volatile, which leads to unreliable dividends and fluctuating share prices. You don’t want to be holding cyclical firms like that until you retire, without looking, because the investment outcome will be uncertain and unpredictable. 

Dividends — one of life’s great pleasures 

Imperial Brands has a strong record of rising dividends, and AstraZeneca has held its dividend steady in recent years as the firm works through a period of difficulty due to expiring patents. The company is rebuilding its product base though, and I think investors will see increases in the dividend down the line. 

At today’s share price of 4,579p, AstraZeneca’s forward dividend yield runs at 4.8% for 2017. At 3,941p, Imperial Brands yields 4.3% for 2017. To me, both firms look like promising candidates to hold until you retire and beyond.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Imperial Brands. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A brilliantly reliable FTSE 100 share I plan to never sell!

This FTSE-quoted share has raised dividends for more than 30 years on the spin! Here's why I plan to hold…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

This 7.7% yielding FTSE 250 stock is up 24% in a year! Have I missed the boat?

When a stock surges, sometimes it can be too late to buy shares and capitalise. Is that the case with…

Read more »

Investing Articles

£13,200 invested in this defensive stock bags me £1K of passive income!

Building a passive income stream is possible and this Fool breaks down one investment in a single stock that could…

Read more »

Investing Articles

I think the Rolls-Royce dividend is coming back – but when?

The Rolls-Royce dividend disappeared in 2020 and has not come back. But with the company performance improving, might it reappear?

Read more »

British Pennies on a Pound Note
Investing Articles

Should I snap up this penny share in March?

Our writer is considering penny shares to buy for his portfolio next month. Does this mining company merit a place…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

Stock market bubble – or start of a bull run?

Christopher Ruane considers whether the surging NVIDIA share price could be symptomatic of a wider stock market bubble forming.

Read more »

Investing Articles

Buying 8,254 Aviva shares in an empty ISA would give me a £1,370 income in year one

Harvey Jones is tempted to add Aviva shares to his Stocks and Shares ISA this year. Today’s 7.37% yield isn't…

Read more »

Investing Articles

Is the tide turning for bank shares?

Bank shares are trading on stubbornly cheap-looking valuations yet business performance in the sector is broadly robust. Should our writer…

Read more »